Does Molina Healthcare Cover Prolia?

What Is Prolia and Why Do Patients Need Insurance Coverage?

Prolia is a RANK ligand inhibitor given as a 60 mg subcutaneous injection every six months to reduce fracture risk in high-risk patients. The drug is not cheap. Without coverage, a single dose can cost between $1,200 and $1,600 at retail pharmacy rates, putting the annual out-of-pocket total near $3,200 for patients who pay cash. Insurance coverage is not optional for most people on fixed incomes.

Denosumab works by blocking RANK ligand, the signaling protein that activates osteoclasts. Fewer active osteoclasts means less bone resorption and measurably higher bone mineral density (BMD). The key FREEDOM trial (N=7,808) showed a 68% relative risk reduction in new vertebral fractures and a 40% reduction in hip fractures over 36 months compared with placebo 1. The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk 2.

Because Prolia is administered in a physician's office rather than self-injected at home, billing routes vary. Office-based administration typically falls under a plan's medical benefit (Part B for Medicare), while specialty pharmacy dispensing may fall under the pharmacy benefit. Molina covers both routes, but the prior authorization (PA) forms differ.

How Molina Healthcare Structures Prolia Coverage

Molina Healthcare operates Medicaid managed care plans in 18 states and Medicare Advantage plans in multiple markets. Prolia coverage exists across both product lines, but the specific formulary tier, copay structure, and PA criteria differ by state contract.

For Molina Medicaid members, denosumab is typically placed on a non-preferred specialty tier requiring PA and step therapy. For Molina Medicare Advantage members, Prolia is usually covered under the Part B medical benefit when administered in a physician's office, which bypasses the pharmacy formulary entirely. Medicare Part B generally pays 80% of the Medicare-allowed amount after the Part B deductible ($240 in 2024), leaving the member responsible for 20% coinsurance 3.

Molina's pharmacy and therapeutics (P&T) committees review specialty drug placements quarterly. The National Committee for Quality Assurance (NCQA) requires Medicaid managed care organizations like Molina to maintain a drug utilization review process consistent with evidence-based guidelines, including those from the Endocrine Society and the National Osteoporosis Foundation 4.

What Prior Authorization Criteria Does Molina Typically Require for Prolia?

Prior authorization is nearly universal for Prolia under Molina plans. The prescribing physician must document several items before Molina will approve the claim.

The standard clinical criteria Molina applies include the following:

Diagnosis confirmation. The member must carry an ICD-10 diagnosis of osteoporosis (M81.0), osteoporosis with fracture (M80.x), or a related bone-loss condition. A dual-energy X-ray absorptiometry (DXA) scan result showing a T-score of <-2.5 at the lumbar spine, femoral neck, or total hip satisfies this requirement for most state plans. Members with a T-score between <-1.0 and <-2.5 (osteopenia) may qualify if they have a history of low-trauma fragility fracture, consistent with American College of Rheumatology guidance 5.

Step therapy (fail-first) requirements. Most Molina Medicaid plans require documented failure, intolerance, or contraindication to at least one generic oral bisphosphonate before approving Prolia. Alendronate 70 mg weekly is the most common first-step agent required. Risedronate 35 mg weekly is an acceptable alternative in many state plans. "Failure" is typically defined as a new fracture or continued BMD loss after 12 months of adherent bisphosphonate therapy.

Prescriber qualifications. Some state Molina plans require that the prescribing clinician be a rheumatologist, endocrinologist, or other bone-specialist rather than a primary care provider. Verify this with the specific state plan before submitting.

Laboratory requirements. Serum calcium and vitamin D 25-OH levels within the last 90 days are often required to rule out hypocalcemia, which is a known adverse effect of denosumab and a contraindication per the FDA label 2.

Approval periods are typically 12 months, covering two doses. Reauthorization requires updated DXA data or clinical documentation of ongoing high fracture risk.

How to Submit a Prior Authorization Request to Molina for Prolia

Getting the PA right the first time saves weeks. The submission process follows a predictable path.

Step 1: Obtain the correct PA form. Molina posts state-specific prior authorization forms on its provider portal. Log in at provider.molinahealthcare.com, select the member's state, and search for "denosumab" or "Prolia." Download the form specific to medical versus pharmacy benefit billing, since they are different documents.

Step 2: Gather clinical documentation. Attach the DXA report with the T-score printed numerically, the prescribing clinician's office notes documenting the diagnosis, any records of prior bisphosphonate therapy with dates and reason for discontinuation, and current labs (calcium, 25-OH vitamin D, creatinine).

Step 3: Submit via fax or portal. Most Molina state plans accept PA submissions by secure fax or through the provider portal. Phone submissions are generally not accepted for specialty drugs. Turnaround time for standard PA decisions is 3 business days under federal Medicaid managed care regulations and 14 days for Medicare Advantage, per CMS requirements.

Step 4: Follow up on day 4. If no decision arrives by business day 4, call Molina's provider services line and ask for the PA tracking number status. Document the call with the representative's name and time.

Physicians who find this process burdensome may benefit from designating a medical assistant trained in specialty drug PA workflows. A 2022 analysis in the American Journal of Managed Care found that practices using dedicated PA staff reduced denial rates for specialty biologics by 23% compared with practices where clinicians handled PA themselves 6.

What If Molina Denies the Prolia Prior Authorization?

Denials happen. They are not final.

Molina must provide a written denial notice that includes the specific clinical rationale and the member's appeal rights. Federal regulations under 42 CFR 438.408 require Medicaid managed care plans to resolve standard appeals within 30 days and expedited appeals (where delay would jeopardize health) within 72 hours 7.

Level 1 Internal Appeal. Submit a written appeal with additional clinical evidence. Useful additions include a letter of medical necessity from the treating physician explicitly addressing each denial criterion, peer-reviewed literature supporting Prolia's use in the member's specific clinical situation (for example, citing the FREEDOM trial for postmenopausal osteoporosis 1), and any documentation that oral bisphosphonates are contraindicated due to esophageal dysmotility, renal insufficiency (eGFR <35 mL/min/1.73m2), or documented GI intolerance.

Level 2 External Independent Review. If Molina upholds the denial after an internal appeal, the member has the right to request review by an independent review organization (IRO). IRO decisions are binding on the plan in most states. The external review process is mandated under the ACA for all marketplace-compliant plans and under Medicaid managed care federal rules.

State Fair Hearing. Medicaid members have an additional right to a state fair hearing before an administrative law judge. Requesting a fair hearing simultaneously with the internal appeal preserves timeline rights in most states.

A well-documented appeal that directly addresses the plan's denial criteria succeeds at a meaningfully higher rate than a generic request for reconsideration.

Rebound Fracture Risk: Why Uninterrupted Coverage Matters Clinically

Coverage gaps are not merely inconvenient. They carry real clinical risk with denosumab.

Unlike bisphosphonates, which embed in bone matrix and provide residual effect for months after discontinuation, denosumab's effect on osteoclast suppression reverses within 6 to 12 months of a missed dose. Multiple case series and the long-term FREEDOM Extension data (total follow-up 10 years) confirm that discontinuing denosumab without transitioning to a bisphosphonate raises the risk of multiple new vertebral fractures within 12 months, a phenomenon now called rebound-associated vertebral fractures (RAVFs) 8.

The Endocrine Society 2019 clinical practice guideline on pharmacological management of osteoporosis states explicitly: "When denosumab is discontinued, patients should be transitioned to bisphosphonate therapy to prevent rapid bone loss and potential rebound vertebral fractures" 9.

For Molina members experiencing a coverage gap, this clinical reality should be communicated to the insurer during the appeal as a patient safety argument. A gap in Prolia dosing is not the same as a gap in a monthly pill. The 6-month injection schedule leaves no room for administrative delay.

Bisphosphonate Step Therapy: When It Applies and When It Doesn't

Step therapy requiring a prior bisphosphonate trial is common in Molina Medicaid plans. Several clinical scenarios create a legitimate bypass path.

Renal insufficiency. Oral bisphosphonates (alendronate, risedronate, ibandronate) carry FDA label warnings against use when creatinine clearance falls below 30 to 35 mL/min 10. Denosumab requires no dose adjustment in renal impairment and may be the appropriate first-line agent in patients with stage 3b or 4 chronic kidney disease. Documenting an eGFR below the bisphosphonate threshold is typically sufficient to bypass the step therapy requirement.

Esophageal contraindications. Patients unable to remain upright for 30 to 60 minutes after oral bisphosphonate administration (due to neurological conditions, severe GERD, Barrett's esophagus, or esophageal stricture) have a documented contraindication. Attach relevant gastroenterology notes.

Prior fracture on bisphosphonate therapy. A patient who sustained a hip or vertebral fracture while adherent to alendronate for 12 months has clearly failed step therapy. Attach pharmacy fill records showing adherence (medication possession ratio of 80% or higher is the standard threshold) and the imaging report confirming the fracture.

Osteonecrosis or atypical femur fracture history. A member with a history of bisphosphonate-related osteonecrosis of the jaw (BRONJ) or an atypical femoral fracture on bisphosphonate therapy has a documented intolerance that justifies direct access to Prolia. Attach the relevant surgical or imaging records.

Documenting any of these bypass criteria clearly in the PA submission reduces the likelihood of a step therapy denial.

Prolia Coverage Under Molina Medicare Advantage vs. Molina Medicaid

The benefit structure for Prolia differs substantially depending on which Molina product the member holds.

Molina Medicare Advantage (Part C/Part B route). When a physician administers Prolia in the office and bills under the medical benefit using HCPCS code J0897, the claim routes through Part B. Molina Medicare Advantage plans cover the drug at the plan's Part B cost-sharing rate, typically 20% coinsurance after the Part B deductible. Some Molina Medicare Advantage plans have $0 copay for select Part B administered drugs; the specific plan's Evidence of Coverage document is the authoritative source. PA requirements under Medicare Advantage must comply with CMS's 2024 final rule on Medicare Advantage prior authorization, which mandates coverage decisions be based on Medicare coverage policy (not plan-specific criteria that differ from Medicare guidelines) 11.

Molina Medicaid. Medicaid formulary placement and PA criteria are set by each state's Medicaid agency and implemented by Molina under its managed care contract. Generic bisphosphonates are almost universally preferred agents. Prolia sits on non-preferred or specialty tiers. Step therapy is standard. Members with dual eligibility (Medicare and Medicaid) generally have Prolia billed through Medicare first, with Medicaid as secondary payer for cost-sharing.

Marketplace/Exchange plans (ACA). Molina participates in ACA marketplace plans in several states. Prolia coverage under marketplace plans follows ACA essential health benefit rules. PA criteria apply, but step therapy override protections in many states (including California, Texas, and Florida) require plans to grant exceptions within a defined timeframe if the prescribing clinician certifies the preferred drug is contraindicated or clinically inappropriate.

What Does Prolia Actually Cost With and Without Molina Coverage?

Understanding cost benchmarks helps members and clinicians set expectations before the PA decision arrives.

Without any insurance, the average wholesale price (AWP) of Prolia 60 mg/mL is approximately $1,400 per prefilled syringe as of mid-2024, based on published red book pricing. Annual treatment (two injections) costs approximately $2,800 at AWP before administration fees.

With approved Molina Medicaid coverage, most members pay $0 to $3 per dose under federally set Medicaid cost-sharing limits for low-income beneficiaries.

With Molina Medicare Advantage, out-of-pocket cost depends on the plan's Part B cost-sharing design and whether the member has reached the annual out-of-pocket maximum.

Amgen's SupportPlus patient assistance program provides Prolia at no cost to uninsured or underinsured patients meeting income criteria (generally household income at or below 500% of the federal poverty level). Insured patients facing high cost-sharing may access Amgen's co-pay card program, which can cover up to $1,800 per year for eligible commercially insured patients. Patients on government programs (Medicaid, Medicare) are not eligible for commercial co-pay cards but may qualify for the free drug program. Call 1-800-77-AMGEN or visit Amgen Assist 360 directly.

Documentation the Prescriber Must Submit: A Practical Checklist

Incomplete PA submissions are the most common reason for delays and initial denials. Physicians submitting a Prolia PA to Molina should include the following:

1. DXA scan report with numerical T-score at lumbar spine and femoral neck (within 24 months for initial PA; within 36 months for reauthorization in clinically stable patients)
2. ICD-10 diagnosis code(s) on the PA form matching the office notes
3. Dates, doses, and duration of any prior bisphosphonate therapy, with pharmacy fill records if available
4. Reason for bisphosphonate discontinuation or contraindication (use the bypass language from the Endocrine Society guideline if applicable 9)
5. Serum calcium (must be within normal limits; denosumab is contraindicated in hypocalcemia)
6. 25-OH vitamin D level (correction of vitamin D deficiency before the first dose is recommended per the FDA label 2)
7. Serum creatinine or eGFR if renal insufficiency is the bypass criterion
8. Fracture history with imaging reports if applicable
9. Letter of medical necessity signed by the treating physician (not a template signature)
10. HCPCS billing code (J0897 for Prolia 1 mg; submit in units of 60 for the full dose) if billing under the medical benefit

A complete submission arriving with all ten items on the first attempt rarely requires follow-up calls and tends to receive decisions within the standard 3-business-day window.

State-by-State Variation in Molina's Prolia Coverage Policies

Molina operates Medicaid plans in California, Florida, Idaho, Illinois, Michigan, Mississippi, Nevada, New Mexico, New York, Ohio, South Carolina, Texas, Utah, Virginia, Washington, and Wisconsin, among others. Each state Medicaid agency sets the preferred drug list (PDL) and PA criteria independently. Molina implements these locally.

California's Medi-Cal, for example, has adopted preferred drug list criteria aligned closely with the California Department of Health Care Services (DHCS) drug policy, which accepts denosumab for patients with T-score <-2.5 or with a fragility fracture regardless of bisphosphonate history when a specialist recommends it 12.

Texas Medicaid requires prior authorization for Prolia under the Vendor Drug Program, with step therapy broadly applied across Medicaid MCOs including Molina.

Ohio Medicaid's PDL places denosumab as non-preferred, requiring PA and step therapy through oral bisphosphonate.

Because state variation is substantial, always verify the current PDL and PA criteria directly with Molina's provider services line for the specific state plan before submitting. PDLs update quarterly.

When to Request an Expedited Prior Authorization

Federal rules allow expedited (72-hour) PA decisions when the standard timeframe could seriously jeopardize the member's health or their ability to regain maximum function. Prolia qualifies for expedited review in specific scenarios.

A patient already on denosumab who has switched to Molina and faces a coverage gap before the next scheduled injection should request expedited review. The treating physician must submit a written statement explaining that a 6-month injection window is closing and that missing the dose creates rebound fracture risk. Reference the FREEDOM Extension data on RAVFs 8 in the expedited request letter.

A patient with a recent hip fracture who is initiating Prolia for the first time may also qualify for expedited review given the acute clinical context. Attach the hospital or emergency department records.

The expedited PA form is the same document as the standard PA form. The physician marks "expedited" and includes the clinical justification paragraph. Molina must notify the member and prescriber of an expedited decision within 72 hours of receiving all required information 3.